HoldsUp

Huberman Lab · 2025-11-03 · Andrew Huberman (host), David Fajgenbaum

How A Doctor Cured His Own Terminal Disease | Dr. David Fajgenbaum

60 research-tied claims examined: 1 contradicted 7 overstated 2 context 46 supported 4 unverified

46 Supported by research
0:07:13David Fajgenbaumsupportedmoderate

Aspirin reduces the risk of colon cancer recurrence, particularly in individuals with colon cancer who have a mutation in the mTOR pathway.

"aspirin also has been shown to reduce risk of recurrence of colon cancer. Um particularly individuals colon cancer that have a mutation actually in the mTOR pathway." (said at 0:07:13)

Observational evidence from large prospective cohort studies indicates that regular post-diagnosis aspirin use is associated with significantly improved colorectal cancer-specific survival and reduced risk of cancer-related mortality and recurrence, particularly among patients harboring activating mutations in the PI3K/AKT/mTOR signaling pathway (most notably PIK3CA mutations). In landmark molecular pathological epidemiology studies (e.g., Liao et al., NEJM 2012), post-diagnosis aspirin use dramatically reduced cancer-related mortality in patients with mutated PIK3CA (multivariate HR 0.18, 95% CI 0.06–0.61), whereas no significant survival benefit was seen in wild-type tumors. Certainty is moderate due to reliance on observational cohort designs rather than randomized trial evidence.

0:07:49David Fajgenbaumsupportedhigh

Viagra (sildenafil) is repurposed as a treatment for a rare pediatric lung disease by improving blood flow to the lungs.

"it's also been repurposed for a rare pediatric lung disease. Kids were dying cuz they weren't getting enough blood flow to their lungs, and if they take Viagra, they can actually get blood flow to their lungs and and live full lives on Viagra." (said at 0:07:49)

Sildenafil (originally marketed as Viagra and later as Revatio for pulmonary hypertension) is approved and widely used off-label or on-label for pediatric pulmonary arterial hypertension (PAH) and persistent pulmonary hypertension of the newborn (PPHN). PAH is a rare, life-threatening vascular condition where restricted pulmonary blood flow causes heart failure and high mortality. By inhibiting phosphodiesterase-5 (PDE-5), sildenafil promotes nitric oxide-mediated pulmonary vasodilation, lowering pulmonary vascular resistance and improving blood flow to the lungs. Systematic reviews and meta-analyses of randomized controlled trials demonstrate that sildenafil therapy significantly reduces mortality in pediatric PAH (RR = 0.25) and decreases the incidence of pulmonary hypertensive crises.

0:08:46David Fajgenbaumsupportedhigh

In a 1,600-patient trial in India published in the Journal of Clinical Oncology, injecting lidocaine around localized breast cancer tumors 8 to 10 minutes prior to surgery resulted in a 29% reduction in mortality at 5 years.

"There's interesting data, actually a large trial that was done in India um 1,600 patients where women who had localized breast cancer, if they had lidocaine injected around the tumor before surgery, 8 to 10 minutes before surgery, there was a 29% reduction in mortality at 5 years versus those who did not have lidocaine injected." (said at 0:08:46)

A large multicenter randomized controlled trial conducted in India and published in the Journal of Clinical Oncology (Badwe et al., 2023) evaluated 1,600 patients (1,583 analyzed) with early breast cancer. Patients were randomized to receive peritumoral infiltration of 0.5% lidocaine 7-10 minutes prior to surgery versus surgery alone. At a median follow-up of 68 months, peritumoral lidocaine demonstrated a statistically significant 29% reduction in overall mortality risk (hazard ratio 0.71; 95% CI, 0.53 to 0.94; P = .019; 5-year overall survival 90.1% vs. 86.4%).

0:12:56Andrew Huberman (host)supportedmoderate

A 2020 study by the Environmental Working Group estimated that over 200 million Americans are exposed to PFAS forever chemicals through drinking tap water.

"In fact, a 2020 study by the Environmental Working Group estimated that more than 200 million Americans are exposed to PFAS chemicals, also known as forever chemicals, through drinking of tap water." (said at 0:12:56)

A 2020 study by researchers at the Environmental Working Group (Andrews & Naidenko, published in Environmental Science & Technology Letters) evaluated PFAS occurrence datasets across public water supplies in the United States and estimated that over 200 million Americans likely receive drinking tap water contaminated with PFOA and PFOS at concentrations of 1 ng/L or higher.

0:19:22David Fajgenbaumsupportedmoderate

Deficiency of adenosine deaminase 2 (DADA2) is a genetic disorder causing patients to suffer dozens of strokes from infancy, and treatment with TNF inhibitors prevents recurrent strokes in these patients.

"And that's that there's a a rare condition called DADA2. Basically, kids are born with a mutation in a gene that results in them having dozens and dozens of strokes from the time they're born until they usually pass away in their teenage years because of the accumulated effect of literally dozens of strokes... It turns out that if you start kids on a TNF inhibitor, they stop having strokes." (said at 0:19:22)

Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disorder caused by loss-of-function mutations in the ADA2 gene, characterized by systemic vasculopathy and recurrent early-onset ischemic and hemorrhagic strokes. Observational cohort studies consistently demonstrate that treatment with TNF inhibitors (such as etanercept, adalimumab, and infliximab) effectively prevents recurrent ischemic strokes and significantly reduces vasculitic disease activity.

0:24:47David Fajgenbaumsupportedhigh

Thalidomide was originally developed as an anti-nausea drug for pregnant women, was removed from the market due to causing severe limb-reduction birth defects, and was later FDA-approved for leprosy and multiple myeloma due to its anti-angiogenic properties.

"Well, it was originally designed as anti-nausea for um for pregnant women. Um so the thought was that it could help them with their nausea, but it ended up causing horrible birth defects. Children were born without limbs, and so it was taken off the market, but then about 20 years later researchers figured out that it could be effective for leprosy. So it's FDA approved for leprosy, and then what's crazy is that shortly thereafter it got FDA approval for multiple myeloma... And the reason that it can work for leprosy and multiple myeloma, and also the reason that it causes birth defects, is it has a major anti-angiogenic effect." (said at 0:24:47)

The speaker accurately summarizes the regulatory history and pharmacological mechanisms of thalidomide. Thalidomide was introduced in the late 1950s (originally developed as a sedative/tranquilizer and widely prescribed to treat morning sickness in pregnant women) and was withdrawn in the early 1960s after causing severe limb-reduction birth defects (such as phocomelia) in over 10,000 infants. Decades later, it was repositioned and received FDA approvals for erythema nodosum leprosum (a complication of leprosy, approved in 1998) and multiple myeloma (approved in 2006). Its therapeutic efficacy in multiple myeloma and its teratogenic limb defects are heavily mediated by anti-angiogenic, immunomodulatory, and cereblon-binding actions.

0:27:20David Fajgenbaumsupportedlow

PD-1 inhibitors (such as pembrolizumab) produce an objective response in approximately 18% of patients with metastatic angiosarcoma.

"So, we treated Michael as the first patient ever that we're aware of with a PD-1 inhibitor, and he responded so incredibly well. A couple of things happened. One is that his doctors started prescribing it to all patients with angiosarcoma. It turns out it works in about 18% of patients. So, it was a uniformly fatal cancer within 1 year. Now, about 20% of people will live beyond a year" (said at 0:27:20)

A retrospective cohort study evaluating pembrolizumab monotherapy in 25 angiosarcoma patients (72% metastatic, 80% with at least two prior lines of therapy) at MD Anderson Cancer Center reported an objective response rate of exactly 18% (and a disease control rate of 59%). Other prospective trials of anti-PD-1 monotherapy or combinations in advanced/metastatic angiosarcoma have observed response rates in a similar range (13% to 25%). The GRADE certainty is low due to the small sample size and retrospective/single-arm design.

0:11:45Andrew Huberman (host)supportedmoderate

Human body temperature must drop by approximately 1 to 3 degrees to fall and stay deeply asleep, and must increase by 1 to 3 degrees to wake up refreshed.

"And that's because in order to fall and stay deeply asleep, your body temperature actually has to drop by about 1 to 3°. And in order to wake up feeling refreshed and energized, your body temperature actually has to increase by about 1 to 3°." (said at 0:11:45)

The claim accurately reflects human circadian thermoregulatory physiology. Core body temperature (CBT) follows a 24-hour circadian rhythm with an amplitude of approximately 0.5°C to 1.0°C (roughly 1°F to 2–3°F). CBT begins to decline prior to sleep onset (driven largely by distal vasodilation) and continues falling during the early sleep cycles, which facilitates sleep initiation and promotes deep slow-wave sleep. CBT reaches its nadir in the early morning hours (typically 2 to 3 hours before habitual waking) and rises toward morning wake time, facilitating arousal and daytime alertness.

0:27:20David Fajgenbaumsupportedvery low

A patient named Michael with metastatic angiosarcoma achieved long-term remission (over 9 years) after off-label treatment with a PD-1 inhibitor.

"So, we treated Michael as the first patient ever that we're aware of with a PD-1 inhibitor, and he responded so incredibly well. A couple of things happened. One is that his doctors started prescribing it to all patients with angiosarcoma. It turns out it works in about 18% of patients... The other thing it did, specifically for Michael, is that it has put him into now a 9-year remission." (said at 0:27:20)

The case describes Michael, reported in a 2017 case report as the first documented patient with recurrent metastatic angiosarcoma treated with off-label anti-PD-1 immunotherapy (pembrolizumab). The published case report confirmed marked disease regression following 13 cycles of pembrolizumab. Single-patient case reports provide very low certainty evidence regarding general treatment efficacy.

  • supports: Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. (Journal for immunotherapy of cancer 2017) · cited 121x in the literature
    "Although these agents have been used in sarcoma therapy, their ability to treat angiosarcoma has not been reported. Here we describe the case of a 63-year-old man who presented initially with angiosarcoma of the nose and received surgery for the primary. Over 4 years he had recurrent disease in the face and liver and was treated with nab-paclitaxel, surgery, and radioembolization, but continued to have progressive disease. His tumor was found to express PD-L1 and he received off-label pembrolizumab 2 mg/kg every 21 days for 13 cycles with marked shrinkage of his liver disease and no new facial lesions." (abstract, results, passage verified)
    pubmedfull study (doi)
0:32:05Andrew Huberman (host)supportedmoderate

Creatine provides documented, mild cognitive support effects, including under conditions of sleep deprivation.

"Now people are talking about creatine for women, for men, for older people and under conditions of sleep deprivation, for cognitive support. Let's face it. The effects, while documented, are fairly mild for cognitive support, but they're there." (said at 0:32:05)

Systematic reviews, meta-analyses, and randomized controlled trials confirm that creatine supplementation produces small-to-moderate, statistically significant improvements in cognitive domains (such as memory, processing speed, and attention) in healthy adults, older individuals, and under metabolic stressors such as acute sleep deprivation. The speaker's characterization of these cognitive benefits as documented but 'fairly mild' accurately reflects the published effect sizes (e.g., standard mean difference ~0.29–0.31 for memory).

0:32:35Andrew Huberman (host)supportedhigh

Aspirin can be useful for reducing the risk of colon cancer and heart attacks.

"drugs like aspirin that can be very useful potentially for colon cancer and for heart attack, not just for pain." (said at 0:32:35)

The speaker accurately states that aspirin has potential utility for preventing heart attacks (cardiovascular events) and colorectal cancer beyond its standard analgesic use. Large systematic reviews and randomized controlled trial syntheses (such as those conducted for the US Preventive Services Task Force and Cochrane) demonstrate that low-dose aspirin significantly reduces major cardiovascular events and myocardial infarction. While colorectal cancer risk reduction is primarily observed after long-term follow-up (often requiring 10 to 15+ years of exposure/follow-up) and must be weighed against bleeding risks, the potential preventive benefit for both indications is well-documented.

0:34:07David Fajgenbaumsupportedmoderate

Bachmann-Bupp syndrome is caused by a genetic mutation that results in elevated levels of the enzyme ODC1.

"there's a condition called Bachmann-Bupp syndrome where kids are born with a mutation that cause them to have elevated levels of an enzyme called ODC1 and basically they're on feeding tubes, they are wheelchair or bed-bound" (said at 0:34:07)

Bachmann-Bupp syndrome (BABS) is an ultra-rare neurodevelopmental disorder caused by heterozygous gain-of-function mutations near the 3' end of the ODC1 gene. These mutations encode a carboxy-terminally truncated ornithine decarboxylase (ODC) enzyme that escapes proteasomal degradation, leading to cellular accumulation and elevated levels of active ODC1 protein and abnormally high polyamine synthesis. Affected individuals exhibit severe global developmental delay, hypotonia, alopecia, and macrocephaly.

0:34:25David Fajgenbaumsupportedvery low

DFMO, a drug developed for African sleeping sickness, is a covalent binder to ODC1 and can reverse severe symptoms in Bachmann-Bupp syndrome if started early.

"African sleeping sickness medicine actually binds to ODC1 and if you start it early enough in life, these kids get their feeding tube taken out. They might be able to sit up. They can even play with their siblings." (said at 0:34:25)

The speaker's statements accurately describe the mechanism and clinical observations regarding difluoromethylornithine (DFMO / eflornithine) in Bachmann-Bupp syndrome (BABS). Eflornithine, originally approved for West African sleeping sickness (trypanosomiasis), acts as an irreversible/covalent inhibitor of ornithine decarboxylase 1 (ODC1). BABS is an ultra-rare neurodevelopmental polyaminopathy caused by gain-of-function mutations in ODC1 leading to enzyme accumulation, severe hypotonia, developmental delay, and alopecia. Repurposed DFMO treatment in reported pediatric cases has led to substantial clinical improvements, including recovery of muscle tone and motor milestones. Because BABS is an ultra-rare condition, the evidence base is restricted to case reports and small uncontrolled case series, conferring very low GRADE certainty.

0:34:55David Fajgenbaumsupportedvery low

Bachmann-Bupp syndrome has only been described in 20 children in the medical literature.

"In fact, it's only been described in 20 kids, which means there's probably hundreds of kids because the medical literature is typically behind reality." (said at 0:34:55)

Bachmann-Bupp syndrome (BABS) is an ultra-rare autosomal dominant polyaminopathy caused by heterozygous gain-of-function mutations in ODC1, first identified and described in 2018. Across all published medical literature to date, only a very small number of cases (approximately 10 to 20 individuals worldwide) have been documented in case reports and series.

0:35:39David Fajgenbaumsupportedmoderate

Colchicine was utilized approximately 3,000 years ago in Egypt for reducing gout.

"Actually, I learned that it's like 3,000 years ago is when it started being used because gout often occurs in individuals who consume too much alcohol. And so, apparently in like Egypt 3,000 years ago, some of the wealthy people were drinking too much alcohol and somehow they figured out that this molecule colchicine, of course, I think it was a root at the time, could be helpful for reducing gout." (said at 0:35:39)

Historical medical literature confirms that colchicine-containing preparations (derived from plants of the Colchicaceae family, such as Colchicum autumnale / meadow saffron) have been documented for thousands of years to treat joint inflammation and gout. The earliest known description dates back to ancient Egypt around 1500 BC (approximately 3,500 years ago) in the Ebers Papyrus, where colchicum extracts were documented for treating joint swelling and gout-like ailments.

0:37:05David Fajgenbaumsupportedhigh

A specific dose of colchicine significantly reduces cardiovascular risk in patients with a prior heart attack, particularly those with diabetes, and is FDA approved for this indication.

"So, it's a slightly different dose from the one that you use for gouty arthritis, but it has a very substantial reduction in heart disease risk if you had a prior heart attack, and in particular if you had a prior heart attack and you have diabetes. A really, really meaningful reduction. So, it got FDA approval for that particular subpopulation." (said at 0:37:05)

Randomized controlled trial data from the Colchicine Cardiovascular Outcomes Trial (COLCOT) demonstrate that low-dose colchicine (0.5 mg daily) significantly reduces cardiovascular events in patients with a recent myocardial infarction (HR 0.77 overall). In a prespecified subgroup analysis of COLCOT patients with type 2 diabetes and recent MI (PMID: 38181203), colchicine reduced primary composite cardiovascular endpoints by 35% (HR 0.65; 95% CI 0.44-0.96; P = 0.03). In June 2023, the FDA approved low-dose colchicine 0.5 mg (Lodoco) to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic cardiovascular disease (ASCVD). While the FDA approval covers broad ASCVD rather than exclusively the post-MI diabetes subgroup, the therapeutic effect and regulatory approval for secondary cardiovascular prevention match the speaker's claim.

0:42:16David Fajgenbaumsupportedhigh

Glioblastoma brain tumors are uniformly fatal.

"Glioblastoma brain tumors are uniformly fatal. They're horrible." (said at 0:42:16)

The speaker's statement that glioblastoma is 'uniformly fatal' is supported by medical consensus and oncology literature. Glioblastoma is the most aggressive primary brain malignancy in adults. Even with standard-of-care multimodal treatment (maximal surgical resection, radiotherapy, and temozolomide chemotherapy), recurrence is essentially inevitable, median overall survival is approximately 15 months, 5-year survival is below 7%, and the disease is clinically regarded as incurable and uniformly fatal.

0:48:15David Fajgenbaumsupportedhigh

Castleman disease is an atypical lymphoproliferative disorder where hyperactivated immune cells produce cytokines that cause vital organ failure.

"It looks like this thing called Castleman disease." Which is basically what we call an atypical lymphoproliferative disorder. So it's kind of like lymphoma, but it's got features that are more like an autoimmune disease. And so basically your immune system becomes highly activated and starts attacking all your vital organs. So the reason that all my organs were shutting down is because my immune system was producing cytokines and other factors that were basically shutting it down." (said at 0:48:15)

The speaker accurately describes Castleman disease (specifically idiopathic multicentric Castleman disease, iMCD) as a lymphoproliferative disorder characterized by immune hyperactivation, excessive cytokine/chemokine release (cytokine storm, frequently involving interleukin-6), and resultant multi-organ failure. This characterization aligns with international consensus diagnostic guidelines and published clinical research.

0:49:26David Fajgenbaumsupportedvery low

A study showed that severe multi-day sleep deprivation in mice causes fatal cytokine storms involving interleukin-6, and blocking these cytokines prolongs survival.

"there was a paper that was published a couple years ago, I think it was in Cell, where mice that were sleep-deprived, like significantly multi-day sleep-deprived, what actually killed them was a cytokine storm due to their immune system producing all these cytokines... But again, in these mouse studies, the actual thing that killed them was their immune system producing cytokines, including interleukin 6, which is an important cytokine in Castleman's. And by just trying a couple medicines that basically blocked the production of some cytokines, you could keep the mice alive longer." (said at 0:49:26)

The speaker accurately recounts a 2023 study published in Cell (Sang et al., PMID 38016470). The authors established a multi-day sleep deprivation paradigm in mice (awake ~96% of the time), finding that after 4 days roughly 80% of mice died exhibiting multi-organ damage, elevated proinflammatory cytokines (including IL-6 and TNF-α), and a cytokine-storm-like syndrome driven by central PGD2 efflux into the periphery. Inhibiting the PGD2/DP1 signaling pathway or blocking inflammatory mediators markedly reduced inflammation and extended survival. As the evidence is restricted to preclinical mouse models, GRADE certainty is very low.

  • supports: Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals. (Cell 2023) · cited 257x in the literature
    "Here, we report a "curling prevention by water" paradigm wherein mice remain awake 96% of the time. After 4 days of exposure, mice exhibit severe inflammation, and approximately 80% die. Sleep deprivation increases levels of prostaglandin D 2 (PGD 2 ) in the brain, and we found that elevated PGD 2 efflux across the blood-brain-barrier-mediated by ATP-binding cassette subfamily C4 transporter-induces both accumulation of circulating neutrophils and a cytokine-storm-like syndrome. Experimental disruption of the PGD 2 /DP1 axis dramatically reduced sleep-deprivation-induced inflammation." (abstract, results)
    pubmedfull study (doi)
0:52:03David Fajgenbaumsupportedmoderate

Stress triggers flares in people with autoimmune diseases.

"I think there's really strong data that among people who have autoimmune diseases stress results in flares of their autoimmune diseases. And so if you have it, stress, lack of sleep, all this reserve can can result in flares." (said at 0:52:03)

Substantial clinical and epidemiological literature demonstrates that psychological stress and related factors (such as sleep disruption) are associated with disease flares and exacerbations across various autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease. Neuroendocrine mechanisms involving the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system alter cytokine profiles and immune regulation, precipitating disease activity.

0:53:40David Fajgenbaumsupportedhigh

Tocilizumab was discovered by Dr. Kazuyuki Yoshizaki in Japan for Castleman disease and later repurposed in the US for rheumatoid arthritis and other autoimmune diseases.

"It's called tocilizumab and um it was made by a a doctor named Kazuyuki Yoshizaki or discovered by a doctor named Kazuyuki Yoshizaki... So, he studied it in Castleman's patients, he got approval for Castleman's in Japan, um and then it got repurposed for rheumatoid arthritis here in the US and a number of other autoimmune diseases." (said at 0:53:40)

The statement accurately reflects the history of tocilizumab. Dr. Kazuyuki Yoshizaki and colleagues at Osaka University (in collaboration with Chugai Pharmaceutical) identified interleukin-6 (IL-6) as the key driver of Castleman disease and developed/tested the humanized anti-IL-6 receptor monoclonal antibody tocilizumab. Tocilizumab received its initial regulatory approval in Japan for Castleman disease (2005) before subsequent worldwide approvals and clinical translation for rheumatoid arthritis and other autoimmune/inflammatory indications in the US and internationally.

0:54:40David Fajgenbaumsupportedhigh

Tocilizumab is effective in approximately one-third of Castleman disease patients.

"We tried that drug from from Kazu from Japan. It didn't work for me. It works in about a third of patients." (said at 0:54:40)

Anti-interleukin-6 (IL-6) targeted therapy for idiopathic multicentric Castleman disease (iMCD)—originally pioneered in Japan by Dr. Kazuyuki Yoshizaki and colleagues—demonstrates durable clinical and radiological efficacy in approximately one-third of patients. In the landmark multinational, double-blind, randomized controlled trial of the anti-IL-6 antibody siltuximab (Lancet Oncology, 2014), durable tumor and symptomatic response occurred in 34% (18 of 53) of patients compared to 0% in the placebo group. Systematic reviews confirm that IL-6 blockade achieves primary durable response in roughly one-third to under 50% of iMCD cases.

0:32:05Andrew Huberman (host)supportedhigh

Creatine supplementation increases muscle strength.

"Taking creatine since my teens cuz I heard back then that it would help make me stronger. It will make you stronger." (said at 0:32:05)

Extensive randomized controlled trials and meta-analyses consistently demonstrate that creatine supplementation, particularly when paired with resistance training, significantly increases muscular strength across both upper- and lower-body compound movements compared to placebo.

0:42:35David Fajgenbaumsupportedmoderate

During brain tumor resections in eloquent areas such as the left hemisphere, awake craniotomy with intraoperative speech testing is used to identify functional boundaries and prevent speech deficits.

"And they did a surgery where they put you to sleep to open up your skull, and then they actually wake you up while your skull's open. And the reason for that, which you're very familiar with, is that as they're cutting out, particularly on the left side of the brain, cutting out parts of the brain tumor, you want to be able to see how far you want to go. You ask people to speak, and sort of when they start slurring their speech, you stop cutting." (said at 0:42:35)

Awake craniotomy with intraoperative speech and language mapping (often using direct electrical stimulation and real-time verbal tasks) is standard neurosurgical practice during the resection of brain tumors located in eloquent regions, particularly the dominant (usually left) hemisphere. Multiple systematic reviews and meta-analyses demonstrate that awake language mapping helps identify functional boundaries, optimizes the extent of resection, and significantly reduces the incidence of persistent postoperative speech and neurological deficits compared to general anesthesia.

1:02:01David Fajgenbaumsupportedmoderate

There are approximately 4,000 FDA-approved drugs and 18,000 known human diseases.

"It's all FDA-approved drugs, all 4,000, and all 18,000 human diseases." (said at 1:02:01)

The speaker's statement refers to standard figures in biomedical informatics and drug repurposing databases (such as PrimeKG and disease ontologies like Mondo). Standard biomedical knowledge graphs and regulatory resources map approximately ~4,000 FDA-approved drugs/formulations against approximately 17,000–18,000 cataloged human diseases.

  • supports: Building a knowledge graph to enable precision medicine. (Scientific data 2023) · cited 493x in the literature
    "Here, we present PrimeKG, a multimodal knowledge graph for precision medicine analyses. PrimeKG integrates 20 high-quality resources to describe 17,080 diseases with 4,050,249 relationships representing ten major biological scales, including disease-associated protein perturbations, biological processes and pathways, anatomical and phenotypic scales, and the entire range of approved drugs with their therapeutic action, considerably expanding previous efforts in disease-rooted knowledge graphs." (abstract, results, passage verified)
    pubmedfull study (doi)
1:09:08David Fajgenbaumsupportedvery low

Cyclosporine and IVIG failed to induce remission in David Fajgenbaum's Castleman disease.

"I thought two drugs might be able to work and we tried both of them. We tried cyclosporine and we tried IVIG and it didn't work. And I got worse and I ended up you know back in the hospital." (said at 1:09:08)

Dr. David Fajgenbaum's clinical course of idiopathic multicentric Castleman disease (iMCD-TAFRO subtype) involved multiple relapses and treatment failures on standard and off-label therapies (including immunomodulators/immunosuppressive regimens and IL-6 blockade) before identifying PI3K/Akt/mTOR signaling activation and achieving prolonged remission with sirolimus. As an individual clinical case history, the evidence certainty is very low.

1:10:18David Fajgenbaumsupportedvery low

Immunohistochemistry and proteomic analysis revealed hyperactivation of the mTOR pathway in lymph node tissue from David Fajgenbaum during a Castleman disease relapse.

"what I discovered was that a communication line in in your immune system or in all of our immune systems called mTOR um was turned into overdrive and I had a lymph node that I had resected during my last relapse where I actually looked at it I stained it for mTOR activation and it came back blazingly positive." (said at 1:10:18)

The published study by Fajgenbaum and colleagues (J Clin Invest, 2019) confirms that quantitative serum proteomics and phospho-S6 (p-S6) immunohistochemical staining of resected lymph node tissue from IL-6-blockade refractory Castleman disease (including Fajgenbaum's own case, who experienced sustained remission on sirolimus) demonstrated hyperactivation of the PI3K/Akt/mTOR signaling pathway. Because this is an N-of-1 mechanistic case investigation and small series (n=3), the GRADE certainty is very low by definition.

1:10:42David Fajgenbaumsupportedhigh

Sirolimus (rapamycin) is FDA-approved for the prevention of organ transplant rejection.

"Sirolimus had never been used before. Rapamycin is the other name for this drug. It had never been used before for Castleman's, but it's approved for organ transplant rejection." (said at 1:10:42)

Sirolimus (also known as rapamycin, brand name Rapamune) was approved by the U.S. FDA in 1999 as an immunosuppressive agent for the prophylaxis of organ rejection in kidney (renal) transplant patients, and it continues to serve as a standard therapy in solid-organ transplantation.

1:13:54David Fajgenbaumsupportedvery low

A 13-year-old pediatric patient with life-threatening Castleman disease at Children's Hospital of Philadelphia achieved disease reversal and remission following treatment with sirolimus.

"the fourth patient we treated was a patient named Joey who was a child um who was a 13-year-old boy at um Children's Hospital of Philadelphia. And um it completely turned his disease around. He was He was literally dying in the Children's Hospital. We used sirolimus" (said at 1:13:54)

Published case reports and translational studies by Dr. David Fajgenbaum and colleagues document the use of the mTOR inhibitor sirolimus (rapamycin) to successfully treat life-threatening, anti-IL-6-refractory idiopathic multicentric Castleman disease (iMCD), achieving durable clinical remissions and biomarker normalization. As single-patient and case series evidence, the GRADE certainty is very low by definition.

1:14:38David Fajgenbaumsupportedvery low

A refractory Castleman disease patient in Chicago who failed sirolimus responded successfully to ruxolitinib.

"So there's a young girl named Kayla in a hospital in Chicago wasn't responding to anything and she didn't respond to my drug either, sirolimus. And we recommended her doctor um try ruxolitinib first time ever for Castleman's disease and she responded incredibly well." (said at 1:14:38)

The published medical literature confirms the first reported pediatric case of refractory idiopathic multicentric Castleman disease (iMCD-TAFRO subtype) successfully treated with the JAK1/JAK2 inhibitor ruxolitinib after failing prior lines of therapy (including siltuximab, chemotherapy, and immunosuppressive agents). Proteomic and translational research led by Dr. David Fajgenbaum's group identified hyperactivation of the JAK/STAT3 pathway in siltuximab nonresponders, supporting the off-label use of ruxolitinib in this setting. As evidence is based on isolated case reports, the GRADE certainty is very low.

1:17:48David Fajgenbaumsupportedvery low

A patient with refractory severe Castleman disease in Vancouver achieved remission following treatment with the TNF inhibitor adalimumab, published in the New England Journal of Medicine.

"One of them is a patient um named Al in Vancouver who wasn't responding to any medicines. He also has Castleman's and the subtype that I have, the really deadly one... So, we gave him adalimumab, and he responded incredibly well. He's been doing great now for 2 years, published in the New England Journal of Medicine earlier this year." (said at 1:17:48)

The speaker's account corresponds to a published correspondence in The New England Journal of Medicine describing the identification of elevated TNF signaling and successful targeted treatment with the TNF inhibitor adalimumab in a patient with refractory idiopathic multicentric Castleman disease. As this describes clinical response in an individual case report, the GRADE certainty of the evidence is very low.

1:20:10David Fajgenbaumsupportedlow

In Castleman disease, activated CD4-positive T cells produce excessive amounts of tumor necrosis factor (TNF).

"we believe it's because T cells in Castleman's disease, CD4 positive T cells, are producing too much TNF when they become activated. And we've shown that in the lab." (said at 1:20:10)

The speaker's laboratory (David Fajgenbaum and colleagues) identified tumor necrosis factor (TNF) signaling hyperactivation, particularly originating from activated CD4+ T cells, as a pathological mechanism and therapeutic target in idiopathic multicentric Castleman disease (iMCD), publishing their findings in the New England Journal of Medicine in 2025 ('Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman's Disease'). Because this represents mechanistic and translational laboratory findings, the GRADE certainty is low.

1:24:38David Fajgenbaumsupportedhigh

Ruxolitinib is used in the treatment of the bone marrow disorder myelofibrosis.

"And then we found a drug that's used for bone for bone marrow condition called myelofibrosis um that we thought could also treat Castleman's patients. So there's a young girl named Kayla in a hospital in Chicago wasn't responding to anything and she didn't respond to my drug either, sirolimus. And we recommended her doctor um try ruxolitinib" (said at 1:24:38)

Ruxolitinib is an FDA- and EMA-approved Janus kinase (JAK1/JAK2) inhibitor indicated for the treatment of intermediate- or high-risk myelofibrosis, a chronic myeloproliferative bone marrow disorder. Its efficacy in reducing spleen volume, alleviating disease-related symptoms, and improving overall survival was demonstrated in large phase 3 randomized controlled trials (the COMFORT studies).

1:19:28Andrew Huberman (host)supportedhigh

N-acetylcysteine (NAC) supplementation supports glutathione production and detoxification.

"supplementing with NAC and N-acetylcysteine, both of which can support glutathione production and detoxification." (said at 1:19:28)

N-acetylcysteine (NAC) is a well-established precursor to L-cysteine, the rate-limiting amino acid in intracellular glutathione (GSH) biosynthesis. Clinical and biochemical evidence demonstrates that NAC supplementation replenishes cellular glutathione levels and supports phase II detoxification pathways, most notably utilized as the standard clinical antidote for acetaminophen toxicity to restore depleted hepatic glutathione pools.

1:32:45Andrew Huberman (host)supportedhigh

Tryptophan is an amino acid in the serotonin synthesis pathway that induces sleep.

"tryptophan the amino acid to induce sleep because it's a you know, it's in the serotonin synthesis pathway" (said at 1:32:45)

Tryptophan is an essential amino acid and the primary dietary precursor for the synthesis of serotonin (5-hydroxytryptamine) and subsequently melatonin. Systematic reviews and meta-analyses of randomized controlled trials demonstrate that tryptophan supplementation aids sleep by significantly reducing wake after sleep onset (WASO) and sleep latency.

1:32:55Andrew Huberman (host)supportedhigh

Contaminated tryptophan batches originating from Japan caused severe illness and death, leading to a long-term ban on its sale.

"the binders used in a particular batch of tryptophan that I think was sold out of Japan although um ended up being contaminated and somebody got very ill and died. You couldn't buy tryptophan for a long time." (said at 1:32:55)

The host's statement accurately captures the historical event. In 1989, an outbreak of eosinophilia-myalgia syndrome (EMS), resulting in severe illness and dozens of deaths, was traced to contaminated L-tryptophan manufactured by the Japanese chemical company Showa Denko K.K. The contamination arose during a modified fermentation/purification process (producing impurities like Peak E and Peak AAA) rather than from tablet binders per se, but the epidemic prompted an FDA nationwide recall and prolonged restriction on over-the-counter sales of L-tryptophan dietary supplements.

1:36:00Andrew Huberman (host)supportedmoderate

Nicotine itself is not carcinogenic.

"smoking will kill you, but it nicotine isn't carcinogenic." (said at 1:36:00)

Nicotine itself is not classified as a carcinogen by major health and regulatory authorities, including the International Agency for Research on Cancer (IARC) and the US Surgeon General. The primary carcinogenic risks of smoking are caused by toxic combustion products and tobacco-specific nitrosamines (such as NNK and NNN), polycyclic aromatic hydrocarbons (PAHs), and aromatic amines. While preclinical (in vitro and animal) studies indicate that nicotine can act as a tumor promoter by stimulating cell proliferation, angiogenesis, and inhibiting apoptosis, evidence does not establish nicotine alone as a complete or DNA-reactive carcinogen.

1:36:10Andrew Huberman (host)supportedhigh

Nicotine raises blood pressure and acts as a vasoconstrictor.

"Nicotine, despite raising blood pressure... It's a constrictor." (said at 1:36:10)

Extensive clinical trial and human physiological evidence demonstrates that acute nicotine exposure stimulates the sympathetic nervous system and catecholamine release, resulting in acute elevations in systolic and diastolic blood pressure, increased peripheral vascular resistance, and arterial vasoconstriction.

1:38:10David Fajgenbaumsupportedmoderate

Emerging clinical evidence shows improvement in Parkinson's disease symptoms in patients taking GLP-1 receptor agonists.

"there's interesting evidence emerging and you'll know better than I will. Um but around improvement in Parkinson's symptoms in patients that are on GLP-1s and have Parkinson's disease." (said at 1:38:10)

The statement that there is 'emerging clinical evidence' of symptom improvement in Parkinson's disease with GLP-1 receptor agonists is supported by Phase 2 randomized controlled trials. A Phase 2 trial of exenatide (Lancet, 2017) and the LIXIPARK trial of lixisenatide (NEJM, 2024) both reported statistically significant reductions in motor disability progression on the MDS-UPDRS Part III score. However, this emerging signal is mixed, as a subsequent larger Phase 3 trial of exenatide (Lancet, 2025) and recent meta-analyses found no statistically significant benefit over placebo.

1:38:30David Fajgenbaumsupportedlow

GLP-1 receptor agonists are associated with a reduced risk of Alzheimer's disease and breast cancer.

"Improvements or reduction in risk of Alzheimer's and also breast cancer people who are on GLP-1s." (said at 1:38:30)

Observational cohort studies and meta-analyses have found that GLP-1 receptor agonist use is associated with a reduced risk of Alzheimer's disease (and all-cause dementia) and breast cancer incidence, particularly in populations with overweight, obesity, or type 2 diabetes. However, the evidence is derived primarily from retrospective observational studies and electronic health record databases, which carry significant heterogeneity and residual confounding (GRADE certainty is low), and some meta-analyses report mixed findings across active comparators.

1:39:00David Fajgenbaumsupportedhigh

Sirolimus (rapamycin) is a naturally occurring compound discovered in a soil sample from Easter Island (Rapa Nui).

"It's called rapamycin because it was found on the island of Rapa Nui in the soil... So rapamycin or or sirolimus the other name for it was found in the soil of the island of Rapa Nui" (said at 1:39:00)

The speaker's statement is an established historical and scientific fact. Rapamycin (generic name sirolimus) is a natural macrolide compound produced by the bacterium Streptomyces hygroscopicus, which was isolated from soil samples collected on Easter Island (Rapa Nui) in the 1960s.

1:39:35David Fajgenbaumsupportedhigh

Rapamycin was initially investigated as an antifungal before being identified as an immunosuppressant.

"they initially thought that it might be a good drug for as an anti-fungal but it's a lousy anti-fungal. And so they were trying to figure out like what else could it do? And they found out that it's a really potent immunosuppressant." (said at 1:39:35)

Rapamycin (sirolimus) was originally discovered from soil samples collected on Easter Island (Rapa Nui) and initially characterized and reported in 1975 as an antifungal antibiotic produced by Streptomyces hygroscopicus. Subsequent investigation revealed its potent immunosuppressive and anti-proliferative properties, leading to its development and approval as an immunosuppressant for organ transplantation.

1:48:35Andrew Huberman (host)supportedvery low

Electrical stimulation of the anterior midcingulate cortex in awake neurosurgical patients elicits a feeling of confronting a challenge and a drive to lean into it.

"he noticed when he stimulated a subregion called the anterior midcingulate cortex that patients would report in real time that they felt like they were some challenge and a bearing down on them, like going into a storm. Each one described it differently. But that the stimulation also made them feel as if they wanted to lean into that challenge." (said at 1:48:35)

The claim accurately describes the findings of a seminal 2013 case study by Parvizi and colleagues (Neuron). In two awake neurosurgical patients undergoing intracranial monitoring for intractable epilepsy, electrical stimulation delivered specifically to the anterior midcingulate cortex (aMCC) elicited autonomic responses, the subjective feeling of an impending challenge or crisis (such as 'pushing through a storm'), and an accompanying determined motivation to persevere through and overcome it. Because this phenomenon was documented in a case series of two patients, the GRADE certainty is very low.

1:49:30Andrew Huberman (host)supportedmoderate

In superagers who age slowly, the anterior midcingulate cortex maintains its cortical volume compared to age-matched cohorts.

"look at this group of so-called super agers which is a misnomer because they actually age very slowly, Right. >> Yeah. Uh and what you find is that psychologically they report a very strong will to live. And their anterior midcingulate cortex is the one of just several areas that seems to maintain volume as they age >> Wow. relative to these age-matched cohorts." (said at 1:49:30)

Neuroimaging studies comparing cognitive 'superagers' (older adults who maintain youthful episodic memory abilities) to typical age-matched older adults show preserved cortical thickness and structural integrity in specific brain regions, most prominently the anterior midcingulate cortex (aMCC) and nodes within the salience and default mode networks.

1:32:17Andrew Huberman (host)supportedhigh

A patient's death during an early gene therapy clinical trial significantly delayed and set back the development of the gene therapy field.

"You know, it wasn't but gosh, maybe a decade and a half ago that this kid was given gene therapy and died. And that delayed, setback, however you want to view it, uh the whole field of gene therapy by a very long time." (said at 1:32:17)

The speaker refers to the 1999 death of 18-year-old Jesse Gelsinger during an adenoviral vector clinical trial for ornithine transcarbamylase deficiency at the University of Pennsylvania. In the historical and biomedical literature, Gelsinger's death and the ensuing regulatory investigations and clinical trial halts are widely documented as a major setback that significantly delayed and reshaped the entire field of human gene therapy.

1:39:27David Fajgenbaumsupportedhigh

Rapamycin (sirolimus) was approved by the FDA for the prevention of organ transplant rejection.

"and then it sort of got taken off the shelf, and it got approved for organ transplant rejection." (said at 1:39:27)

The claim is fully supported. Rapamycin (sirolimus, originally marketed as Rapamune) was approved by the U.S. FDA as an immunosuppressive agent for the prophylaxis of organ rejection in patients receiving kidney transplants (and used widely in solid organ transplantation).

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.